We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$395M
Cap. Flow %
-10.28%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
7.4 quarters

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD icon
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW icon
WW International
WW
+$487M
2
BPMC icon
Blueprint Medicines
BPMC
+$13.9M
3
ONC icon
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 46.31%
2 Consumer Discretionary 28.3%
3 Miscellaneous 25.15%
4 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$19.8M 0.52%
400,000
-100,000
-20% -$5.09M
2018 Q1
2 quarters
TSRO
27
CALL
DELISTED
TESARO, Inc.
TSRO
$19.5M 0.51%
500,000
+150,000
+43% +$5.3M
2017 Q1
6 quarters
XNCR icon
28
Xencor
XNCR
$1.83B
$19.5M 0.51%
500,000
+100,000
+25% +$4.08M
2017 Q3
4 quarters
BMRN icon
29
CALL
BioMarin Pharmaceuticals
BMRN
$10.6B
$19.4M 0.5%
200,000
– –
2016 Q4
7 quarters
XBI icon
30
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$19.2M 0.5%
+200,000
New +$19.4M
2018 Q3
0 quarters
MU icon
31
CALL
Micron Technology
MU
$1.16T
$18.1M 0.47%
+400,000
New +$20.2M
2018 Q3
0 quarters
MDCO
32
CALL
DELISTED
Medicines Co
MDCO
$17.9M 0.47%
600,000
-100,000
-14% -$3.77M
2017 Q2
5 quarters
C icon
33
CALL
Citigroup
C
$217B
$17.9M 0.47%
+250,000
New +$17.7M
2018 Q3
0 quarters
IFRX icon
34
InflaRx
IFRX
$236M
$17.2M 0.45%
500,000
– –
2018 Q1
2 quarters
ALBO
35
DELISTED
Albireo Pharma Inc
ALBO
$16.5M 0.43%
500,000
– –
2017 Q4
3 quarters
BABA icon
36
CALL
Alibaba
BABA
$277B
$16.5M 0.43%
+100,000
New +$17.7M
2018 Q3
0 quarters
AUTL icon
37
Autolus Therapeutics
AUTL
$482M
$15.3M 0.4%
500,000
-25,000
-5% -$675K
2018 Q2
1 quarter
KYNB icon
38
Kyntra Bio
KYNB
$24.7M
$15.2M 0.4%
10,000
– –
2018 Q1
2 quarters
SAGE icon
39
DELISTED
Sage Therapeutics
SAGE
$14.1M 0.37%
100,000
– –
2016 Q3
8 quarters
ARGX icon
40
argenx
ARGX
$51.9B
$14M 0.37%
185,000
+35,000
+23% +$3.1M
2017 Q3
4 quarters
FCX icon
41
CALL
Freeport-McMoran
FCX
$106B
$13.9M 0.36%
1,000,000
– –
2017 Q4
3 quarters
WYNN icon
42
CALL
Wynn Resorts
WYNN
$7.74B
$12.7M 0.33%
+100,000
New +$14.8M
2018 Q3
0 quarters
AAL icon
43
CALL
American Airlines Group
AAL
$8.45B
$12.4M 0.32%
+300,000
New +$11.7M
2018 Q3
0 quarters
NKTR icon
44
CALL
Nektar Therapeutics
NKTR
$1.41B
$12.2M 0.32%
13,333
-6,667
-33% -$5.69M
2016 Q4
7 quarters
FOLD icon
45
CALL
DELISTED
Amicus Therapeutics
FOLD
$12.1M 0.31%
1,000,000
+500,000
+100% +$6.99M
2017 Q2
5 quarters
MDCO
46
DELISTED
Medicines Co
MDCO
$12M 0.31%
400,000
– –
2016 Q4
7 quarters
AXDX icon
47
CALL
DELISTED
Accelerate Diagnostics
AXDX
$11.5M 0.3%
50,000
– –
2018 Q2
1 quarter
AXDX icon
48
DELISTED
Accelerate Diagnostics
AXDX
$11.5M 0.3%
50,000
– –
2017 Q2
5 quarters
RGNX icon
49
Regenxbio
RGNX
$533M
$11.3M 0.29%
150,000
– –
2015 Q3
12 quarters
DNLI icon
50
Denali Therapeutics
DNLI
$3.11B
$10.9M 0.28%
500,000
– –
2017 Q4
3 quarters
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $395M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.